Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Asciminib is a novel tyrosine kinase inhibitor (TKI) targeting the myristoyl pocket of BCR-ABL rather than the ATP site, thereby potentially overcoming resistan

  • Asciminib demonstrated superior efficacy (MMR at week 24 was 25.5% v. 13.2%) and tolerability (50.6% vs 60.5% >G3 AEs) compared to bosutinib in patients with chronic phase CML after at least 2 prior TKIs.